Biotech Values

[exwannabe]

I'd guess Teva would throw its hands up in the air and withdraw its T Enox application declaring they can't meet the FDA regulations.

Teva would certainly earn more money in the long run getting Momenta's portion of the Sandoz deal rather than competing against Sandoz.

That is a valid point, I think TEVA could would escape any FTC review when we are talking "just another generic" (as long as they avoid a Copox issue).

Of course they could do the same by a reverse settlement of MNTA suit, just accept $100M or such for walking.